Targets › MAPT
18 programs from 17 companies in 21 trials: 11 Phase 1, 6 Phase 2, 4 Phase 3; Neurology, Other, Immunology; next expected readout Dec 2026.
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. (UniProt, P10636)
Open in Phaseline: the race on MAPT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, Irvine | MK-6240 tau PET tracer, binds to tau tangles in the brain | MAPT | Phase 3 | Alzheimer Disease | Dec 2026 |
| Roche | Trontinemab Anti-tau antibody targeting phosphorylated tau | MAPT | Phase 3 | Alzheimers Disease; Alzheimer's Disease | Feb 2028 |
| Bristol-Myers Squibb | BMS-986446 Anti-microtubule-binding region (MTBR) tau monoclonal antibody | MAPT | Phase 2 | Alzheimer Disease, Early Onset; Alzheimer's Disease | Dec 2026 |
| Columbia University | 18F-MK6240 Tau PET imaging tracer that binds to tau protein aggregates | MAPT | Phase 2 | Alzheimer Disease | May 2027 |
| University Hospital, Toulouse | Flortaucipir Tau-specific PET tracer | MAPT | Phase 2 | Alzheimer Disease | Jan 2029 |
| Scott Mcnally | flutemetamol F 18 Amyloid-beta PET imaging agent | MAPT | Phase 2 | Cognitive Impairment | Sep 2030 |
| Adam Boxer | AADvac1 Active immunotherapy targeting tau pathology | MAPT | Phase 2 | Progressive Supranuclear Palsy(PSP) | Sep 2030 |
| Adam Boxer | LM11A-31 Small molecule targeting tau protein and neuroinflammation | MAPT | Phase 2 | Progressive Supranuclear Palsy(PSP) | Sep 2030 |
| Amyloid Solution | AS-S603 Small molecule targeting amyloid-beta and tau aggregates | APP, MAPT | Phase 1 | Healthy | Dec 2026 |
| Texas Tech University Health Sciences Center | Curcumin Polyphenolic compound targeting amyloid-beta aggregation and tau pathology; crosses blood- | ABCB1, APP, MAPT | Phase 1 | Bioavailability | Dec 2026 |
| Eli Radiopharma | [18F]Flortaucipir Injection Tau neurofibrillary tangle (NFT) PET imaging agent - binds to aggregated tau protein | MAPT | Phase 1 | AD - Alzheimer's Disease | Dec 2026 |
| Nuravax | DUVAX Vaccine targeting amyloid-beta and tau proteins | APP, MAPT | Phase 1 | Alzheimer Disease | Apr 2027 |
| Voyager Therapeutics | VY7523 Monoclonal antibody targeting pathological tau | MAPT | Phase 1 | Alzheimer's Disease (AD) | May 2027 |
| Tharick Pascoal | 18F-MK-6240 tau neurofibrillary tangle PET imaging agent | MAPT | Phase 1 | Alzheimer Disease | May 2027 |
| Arrowhead Pharmaceuticals | ARO-MAPT-SC Antisense oligonucleotide targeting MAPT mRNA for reduction of tau protein | MAPT | Phase 1 | Alzheimer Disease | Jun 2027 |
| UCB Biopharma SRL | Bepranemab (UCB0107) Microtubule-associated protein tau inhibitor | MAPT | Phase 1 | Progressive Supranuclear Palsy | Dec 2027 |
| Institute for Molecular Medicine | AV-1980R Recombinant protein tau vaccine targeting pathological tau | MAPT | Phase 1 | Alzheimer Disease | Jun 2029 |
| Oligomerix | OLX-07010 tau self-association inhibitor | MAPT | Phase 1 | Alzheimer Disease | – |
Alzheimer Disease (8) Alzheimer's Disease (2) Alzheimers Disease (2) Progressive Supranuclear Palsy(PSP) (2) AD - Alzheimer's Disease (1) Bioavailability (1) Alzheimer Disease, Early Onset (1) Alzheimer's Disease (AD) (1) Healthy (1) Progressive Supranuclear Palsy (1) Cognitive Impairment (1)
small molecule (11), antibody (3), protein or peptide (2), mixed (2)
Adam Boxer (2) Eli Radiopharma (1) Texas Tech University Health Sciences Center (1) Bristol-Myers Squibb (1) Roche (1) Columbia University (1) Institute for Molecular Medicine (1) Voyager Therapeutics (1) Amyloid Solution (1) University Hospital, Toulouse (1) Arrowhead Pharmaceuticals (1) Tharick Pascoal (1) University of California, Irvine (1) Nuravax (1) Oligomerix (1) UCB Biopharma SRL (1) Scott Mcnally (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.